Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research’s esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc.
Oct 31, 2024
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference.
Oct 30, 2024
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. “I’m excited about the expanding opportunity I
Oct 29, 2024
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024.
Oct 08, 2024
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
Industry veteran brings multidisciplinary expertise leading Mass Spectrometry division at Agilent Technologies to a company building a platform to power next-generation proteomics SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company
Sep 17, 2024
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.
Aug 14, 2024
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. “In Q2, we saw continued progress against core
Jul 30, 2024
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024.
Jul 09, 2024
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 23, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference.
May 23, 2024
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. “We continued to make solid progress against our
Apr 30, 2024
